KPV cost: prescription vs research grade
Published prices by category, checked November 2, 2026. REMEVi does not currently price KPV.
Published monthly figures for compounded KPV range widely by program type, and most predate HHS’s October 2026 policy. Telehealth listings run from the low hundreds of dollars a month upward; clinic programs cost more. KPV is not FDA-approved. REMEVi does not currently price KPV or offer it, and has no KPV product.
KPV is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer KPV.
Published KPV prices by category
| Category | Published figure | What the figure covers | Published by |
|---|---|---|---|
| Telehealth peptide programs | $170 per month | One listed program’s standard protocol; route not stated; listing dated January 2026, before the policy | Telehealth comparison site |
| Telehealth peptide programs | $250–$450 per month | Estimate including virtual visits, medication and basic monitoring; February 2026 | Peptide cost guide |
| Compounded medication (pharmacy charge) | $75–$200 per month | Estimate for the medication alone, on prescription; February 2026 | Peptide cost guide |
| Clinic programs | $400–$700 per month | Estimate for a comprehensive in-person program; February 2026 | Peptide cost guide |
| Research-grade vials | No published price cited (checked 2026-11-02) | The listings found were seller pages, which this page does not link | — |
Figures are as published by third parties and are not REMEVi prices. Most predate the October 30, 2026 policy, so programs may change them.
What the CoA and registered-source rules add
Under the HHS policy, the pharmacy must buy bulk KPV from an FDA-registered facility with a valid certificate of analysis, from a CGMP-compliant manufacturer, and compound one active ingredient per product. Oral KPV also needs documentation that the formulation is adequately bioavailable in humans. Each step costs money, and so does the prescriber’s evaluation and follow-up.
Why “research grade” KPV is cheaper, and what it lacks
Research-grade vials skip the prescription, the 503A pharmacy and the sourcing documentation, so they cost less. They are outside the HHS policy, are not made for a named patient, and carry no requirement for a CoA, a registered source or a bioavailability check. FDA warned five online peptide vendors on August 24, 2026 that “research use only” labels did not outweigh evidence of human use.
REMEVi and KPV
REMEVi does not currently price KPV and does not offer it. What REMEVi does offer, with the same prescription-and-licensed-pharmacy model, is NAD+: From $149 per 4 weeks on the 52-week plan ($1,937 for 13 fills).
More questions
How much does KPV cost?
Published monthly figures for compounded KPV range widely by program type, and most predate HHS’s October 2026 policy. Telehealth listings run from the low hundreds of dollars a month upward; clinic programs cost more. KPV is not FDA-approved. REMEVi does not currently price KPV or offer it, and has no KPV product.
Sources
- Telehealth Ally — KPV: Evidence, FDA Status & Telehealth Providers (status updated Jan 15, 2026) (read November 2, 2026)
- MyPeptideMatch — KPV (Ac-KPV-NH2) Cost in 2026: Pricing, Insurance, and Savings (published Feb 17, 2026) (read November 2, 2026)
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
- Holland & Knight, Oct 16, 2026 — Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·